bioAffinity Technologies Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.67
- Today's High:
- $1.7999
- Open Price:
- $1.7999
- 52W Low:
- $1.31
- 52W High:
- $15.55
- Prev. Close:
- $1.67
- Volume:
- 2196
Company Statistics
- Market Cap.:
- $15.85 million
- Book Value:
- 1.142
- Revenue TTM:
- $5724
- Operating Margin TTM:
- -84590.93%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -51.22%
- Return on Equity TTM:
- -2530.31%
Company Profile
bioAffinity Technologies Inc. had its IPO on 2022-09-01 under the ticker symbol BIAF.
The company operates in the Healthcare sector and Diagnostics & Research industry. bioAffinity Technologies Inc. has a staff strength of 14 employees.
Stock update
Shares of bioAffinity Technologies Inc. opened at $1.8 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.67 - $1.8, and closed at $1.7.
This is a +1.8% increase from the previous day's closing price.
A total volume of 2,196 shares were traded at the close of the day’s session.
In the last one week, shares of bioAffinity Technologies Inc. have slipped by -5.56%.
bioAffinity Technologies Inc.'s Key Ratios
bioAffinity Technologies Inc. has a market cap of $15.85 million, indicating a price to book ratio of 1.3353 and a price to sales ratio of 6847.0483.
In the last 12-months bioAffinity Technologies Inc.’s revenue was $5724 with a gross profit of $0 and an EBITDA of $-4811157. The EBITDA ratio measures bioAffinity Technologies Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, bioAffinity Technologies Inc.’s operating margin was -84590.93% while its return on assets stood at -51.22% with a return of equity of -2530.31%.
In Q1, bioAffinity Technologies Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
bioAffinity Technologies Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into bioAffinity Technologies Inc.’s profitability.
bioAffinity Technologies Inc. stock is trading at a EV to sales ratio of 1685.1347 and a EV to EBITDA ratio of -0.4613. Its price to sales ratio in the trailing 12-months stood at 6847.0483.
bioAffinity Technologies Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.46 million
- Total Liabilities
- $796303.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $32314
- Dividend Payout Ratio
- 0%
bioAffinity Technologies Inc. ended 2024 with $10.46 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.46 million while shareholder equity stood at $9.67 million.
bioAffinity Technologies Inc. ended 2024 with $0 in deferred long-term liabilities, $796303.00 in other current liabilities, 59241.00 in common stock, $-38200258.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.77 million and cash and short-term investments were $9.77 million. The company’s total short-term debt was $168,430 while long-term debt stood at $0.
bioAffinity Technologies Inc.’s total current assets stands at $10.23 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $11027.00 compared to accounts payable of $146537.00 and inventory worth $11335.00.
In 2024, bioAffinity Technologies Inc.'s operating cash flow was $0 while its capital expenditure stood at $32314.
Comparatively, bioAffinity Technologies Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.7
- 52-Week High
- $15.55
- 52-Week Low
- $1.31
- Analyst Target Price
- $
bioAffinity Technologies Inc. stock is currently trading at $1.7 per share. It touched a 52-week high of $15.55 and a 52-week low of $15.55. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $1.78 and 200-day moving average was $1.9 The short ratio stood at 2.61 indicating a short percent outstanding of 0%.
Around 2725.3% of the company’s stock are held by insiders while 115.2% are held by institutions.
Frequently Asked Questions About bioAffinity Technologies Inc.
Similar Industry Stocks (Diagnostics & Research)
+0.11%
Most Active
Top Gainers
Top Losers
About
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.